Your browser doesn't support javascript.
loading
Prediction of relative change in free nerve growth factor following subcutaneous administration of tanezumab, a novel monoclonal antibody to nerve growth factor.
Shoji, Satoshi; Suzuki, Akiyuki; Nouri, Parya; Cai, Chun-Hua; Gaitonde, Puneet; Marshall, Scott.
Affiliation
  • Shoji S; Pharmacometrics, Pfizer R&D Japan, Tokyo, Japan.
  • Suzuki A; Pharmacometrics, Pfizer R&D Japan, Tokyo, Japan.
  • Nouri P; Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA.
  • Cai CH; Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA.
  • Gaitonde P; Clinical Pharmacology, Pfizer Inc., Groton, Connecticut, USA.
  • Marshall S; Pharmacometrics, Pfizer R&D Ltd., Sandwich, UK.
CPT Pharmacometrics Syst Pharmacol ; 12(9): 1358-1370, 2023 09.
Article in En | MEDLINE | ID: mdl-37470295
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Nerve Growth Factor / Antibodies, Monoclonal Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2023 Type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Nerve Growth Factor / Antibodies, Monoclonal Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2023 Type: Article Affiliation country: Japan